The Oslo Medicines Initiative (OMI) has commissioned a series of technical reports to review and analyze the relevant evidence and provide policy considerations as a basis for discussion to inform its work. Reports have been independently authored and externally peer reviewed by experts in the field.

These focus on the following topics:

• Overview of the market for novel medicines in the WHO European Region
• Towards a new vision for shared responsibility in pharmaceutical pricing, coverage and reimbursement: Policy approaches building on principles of solidarity, transparency and sustainability
• New business models for pharmaceutical research and development as a global public good: considerations for the WHO European Region
• Payer policies to support innovation and access to medicines in the WHO European Region
• Policy instruments (non-price) for medical innovation
• Access to information in markets for medicines in the WHO European Region
• Access to high-priced medicines in lower-income countries in the WHO European Region
• The social contract and human rights bases for promoting access to effective, novel, high-priced medicines.